The GZF1 Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population derived from the human NCI-H1975 lung adenocarcinoma cell line. This product provides a loss-of-function model for the zinc finger protein GZF1 (GDNF-inducible zinc finger 1), enabling detailed investigation of its transcriptional regulatory roles. The polyclonal format ensures a heterogeneous pool of edited cells, facilitating robust assessment of functional consequences without clonal selection bias. Intended for advanced biomedical research, these cells serve as a versatile platform for studying gene function in a relevant oncogenic background.
The NCI-H1975 parental cell line is a widely used model of non-small cell lung adenocarcinoma, originally isolated from the pleural effusion of a patient with metastatic disease. It endogenously harbors activating mutations in the epidermal growth factor receptor (EGFR), specifically L858R in exon 21 and T790M in exon 20, which are clinically relevant drivers of tumor growth and therapeutic resistance. The line’s epithelial morphology and tumorigenic properties, combined with its well-defined mutational landscape, make it particularly suited for dissecting oncogenic signaling networks in lung cancer.
GZF1 functions as a zinc finger transcriptional repressor that is rapidly induced downstream of GDNF/Ret receptor tyrosine kinase signaling. Upon activation, GZF1 binds to specific DNA elements and recruits the NCOR1/SMRT?CHDAC1/2 corepressor complexes to silence target genes, including the developmental regulator HOXA10 and the cyclin-dependent kinase inhibitor CDKN1A (p21). This repression modulates cell cycle progression, differentiation, and apoptosis, positioning GZF1 as a critical node linking extracellular survival cues to transcriptional programs. The interaction with HDAC-containing complexes underscores its epigenetic regulatory role.
In the NCI-H1975 background, disruption of GZF1 allows dissection of its contribution to EGFR-driven lung adenocarcinoma pathophysiology. Given the interplay between GDNF/Ret and EGFR signaling, and the documented dysregulation of apoptosis and proliferation in these cells, the knockout model enables evaluation of GZF1’s tumor-suppressive or oncogenic activities. For example, derepression of CDKN1A may restore cell cycle checkpoints, while altered HOXA10 expression could impact differentiation states. The polyclonal nature of the knockout population preserves biological variability, making it suitable for integrating with pharmacological studies, such as EGFR inhibitor sensitivity assays, to assess therapeutic relevance.
Researchers can utilize these knockout cells in diverse experimental approaches. Common readouts include Western blotting and RT-qPCR for GZF1, CDKN1A, and other pathway constituents; cell proliferation and apoptosis assays for functional phenotyping; chromatin immunoprecipitation (ChIP-qPCR) to assess GZF1 genomic occupancy; and co-immunoprecipitation to verify interactions with NCOR1, HDAC1, or HDAC2. The model also supports transcriptional network analysis and identification of downstream effectors in EGFR-mutant lung adenocarcinoma. For further details or technical support, please contact Ascent Research.
